The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer

Journal of Cell Science

Volumn 122, Issue 16, 2009, Pages 2906-2913

  Moncada Pazos, Angela ^a   Obaya, Alvaro J ^b   Fraga, Mario F ^c   Viloria, Cristina G ^a   Capellá, Gabriel ^d   Gausachs, Mireia ^d   Esteller, Manel ^c   López Otín, Carlos ^a   Cal, Santiago ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Degradome; Metalloprotease; Methylation; Thrombospondin

Indexed keywords

ADAMTS12 METALLOPROTEASE; METALLOPROTEINASE; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAMTS12 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DEGRADATION KINETICS; EPIGENETICS; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; GENE ACTIVATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; STROMA; TUMOR CELL; BIOSYNTHESIS; COLON TUMOR; DISEASE COURSE; DNA METHYLATION; ENZYME INDUCTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; STROMA CELL; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

MUS;

ADAM PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; PROMOTER REGIONS, GENETIC; STROMAL CELLS; TRANSCRIPTIONAL ACTIVATION;

EID: 70350036203     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.050468     Document Type: Article

References (46)

1. Aguilera, O., Fraga, M. F., Ballestar, E., Paz, M. F., Herranz, M., Espada, J., Garcia, J. M., Munoz, A., Esteller, M. and Gonzalez-Sancho, J. M. (2006). Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25, 4116-4121.
2. Apte, S. S. (2004). A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int. J. Biochem. Cell Biol. 36, 981-985.
3. Balbin, M., Fueyo, A., Tester, A. M., Pendas, A. M., Pitiot, A. S., Astudillo, A., Overall, C. M., Shapiro, S. D. and Lopez-Otin, C. (2003). Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 35, 252-257.
4. Bibikova, M., Lin, Z., Zhou, L., Chudin, E., Garcia, E. W., Wu, B., Doucet, D., Thomas, N. J., Wang, Y., Vollmer, E. et al. (2006). High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 16, 383-393.
5. Bondeson, J., Wainwright, S., Hughes, C. and Caterson, B. (2008). The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin. Exp. Rheumatol. 26, 139-145.
6. Cal, S., Arguelles, J. M., Fernandez, P. L. and Lopez-Otin, C. (2001). Identification, characterization, and intracellular processing of ADAM-TS12, a novel human disintegrin with a complex structural organization involving multiple thrombospondin-1 repeats. J. Biol. Chem. 276, 17932-17940.
7. Cal, S., Obaya, A. J., Llamazares, M., Garabaya, C., Quesada, V. and Lopez-Otin, C. (2002). Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 283, 49-62.
8. Chang, C. F., Westbrook, R., Ma, J. and Cao, D. (2007). Transforming growth factorbeta signaling in breast cancer. Front. Biosci. 12, 4393-4401.
9. Cross, N. A., Chandrasekharan, S., Jokonya, N., Fowles, A., Hamdy, F. C., Buttle, D. J. and Eaton, C. L. (2005). The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 63, 269-275.
10. Dunn, J. R., Panutsopulos, D., Shaw, M. W., Heighway, J., Dormer, R., Salmo, E. N., Watson, S. G., Field, J. K. and Liloglou, T. (2004). METH-2 silencing and promoter hypermethylation in NSCLC. Br. J. Cancer 91, 1149-1154.
11. Egeblad, M. and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
12. Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286-298.
13. Freije, J. M., Balbin, M., Pendas, A. M., Sanchez, L. M., Puente, X. S. and Lopez- Otin, C. (2003). Matrix metalloproteinases and tumor progression. Adv. Exp. Med. Biol. 532, 91-107.
14. Gabbiani, G. (2003). The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200, 500-503.
15. Gutierrez-Fernandez, A., Fueyo, A., Folgueras, A. R., Garabaya, C., Pennington, C. J., Pilgrim, S., Edwards, D. R., Holliday, D. L., Jones, J. L., Span, P. N. et al. (2008). Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res. 68, 2755-2763.
16. Held-Feindt, J., Paredes, E. B., Blomer, U., Seidenbecher, C., Stark, A. M., Mehdorn, H. M. and Mentlein, R. (2006). Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int. J. Cancer 118, 55-61.
17. Iruela-Arispe, M. L., Carpizo, D. and Luque, A. (2003). ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann. NY Acad. Sci. 995, 183-190.
18. Jin, H., Wang, X., Ying, J., Wong, A. H., Li, H., Lee, K. Y., Srivastava, G., Chan, A. T., Yeo, W., Ma, B. B. et al. (2007). Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 26, 7490-7498.
19. Kikuchi, Y., Kashima, T. G., Nishiyama, T., Shimazu, K., Morishita, Y., Shimazaki, M., Kii, I., Horie, H., Nagai, H., Kudo, A. et al. (2008). Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J. Histochem. Cytochem. 56, 753-764.
20. Kuno, K., Bannai, K., Hakozaki, M., Matsushima, K. and Hirose, K. (2004). The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem. Biophys. Res. Commun. 319, 1327-1333.
21. Lee, N. V., Sato, M., Annis, D. S., Loo, J. A., Wu, L., Mosher, D. F. and Iruela-Arispe, M. L. (2006). ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J. 25, 5270-5283.
22. Lind, G. E., Kleivi, K., Meling, G. I., Teixeira, M. R., Thiis-Evensen, E., Rognum, T. O. and Lothe, R. A. (2006). ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol. 28, 259-272.
23. Liu, Y. J., Xu, Y. and Yu, Q. (2006). Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 25, 2452-2467.
24. Llamazares, M., Obaya, A. J., Moncada-Pazos, A., Heljasvaara, R., Espada, J., LopezOtin, C. and Cal, S. (2007). The ADAMTS12 metalloproteinase exhibits antitumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J. Cell Sci. 120, 3544-3552.
25. Lo, P. H., Leung, A. C., Kwok, C. Y., Cheung, W. S., Ko, J. M., Yang, L. C., Law, S., Wang, L. D., Li, J., Stanbridge, E. J. et al. (2007). Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. Oncogene 26, 148-157.
26. Lopez-Otin, C. and Overall, C. M. (2002). Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 3, 509-519.
27. Lopez-Otin, C. and Matrisian, L. M. (2007). Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808.
28. Lopez-Otin, C. and Bond, J. S. (2008). Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 283, 30433-30437.
29. Luque, A., Carpizo, D. R. and Iruela-Arispe, M. L. (2003). ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem. 278, 23656-23665.
30. Martin, M. D. and Matrisian, L. M. (2007). The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 26, 717-724.
31. Masui, T., Hosotani, R., Tsuji, S., Miyamoto, Y., Yasuda, S., Ida, J., Nakajima, S., Kawaguchi, M., Kobayashi, H., Koizumi, M. et al. (2001). Expression of METH-1 and METH-2 in pancreatic cancer. Clin. Cancer Res. 7, 3437-3443.
32. Micke, P. and Ostman, A. (2004). Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 45 Suppl. 2, S163-S175.
33. Mirochnik, Y., Kwiatek, A. and Volpert, O. V. (2008). Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr. Drug Targets 9, 851-862.
34. Mueller, M. M. and Fusenig, N. E. (2004). Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4, 839-849.
35. Overall, C. M. and Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657-672.
36. Porter, S., Scott, S. D., Sassoon, E. M., Williams, M. R., Jones, J. L., Girling, A. C., Ball, R. Y. and Edwards, D. R. (2004). Dysregulated expression of adamalysinthrombospondin genes in human breast carcinoma. Clin. Cancer Res. 10, 2429-2440.
37. Porter, S., Clark, I. M., Kevorkian, L. and Edwards, D. R. (2005). The ADAMTS metalloproteinases. Biochem. J. 386, 15-27.
38. Puente, X. S., Sanchez, L. M., Overall, C. M. and Lopez-Otin, C. (2003). Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4, 544-558.
39. Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J. M., Noel, A. and Cataldo, D. (2008). Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 90, 369-379.
40. Ronnov-Jessen, L., Petersen, O. W. and Bissell, M. J. (1996). Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76, 69-125.
41. Sadler, J. E. (2008). Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112, 11-18.
42. Shimazaki, M. and Kudo, A. (2008). Impaired capsule formation of tumors in periostinnull mice. Biochem. Biophys. Res. Commun. 367, 736-742.
43. Sugimoto, H., Mundel, T. M., Kieran, M. W. and Kalluri, R. (2006). Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 5, 1640-1646.
44. Trzpis, M., McLaughlin, P. M., de Leij, L. M. and Harmsen, M. C. (2007). Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol. 171, 386-395.
45. Vazquez, F., Hastings, G., Ortega, M. A., Lane, T. F., Oikemus, S., Lombardo, M. and Iruela-Arispe, M. L. (1999). METH-1, a human ortholog of ADAMTS-1, and METH- 2 are members of a new family of proteins with angio-inhibitory activity. J. Biol. Chem. 274, 23349-23357.
46. Wang, W. M., Lee, S., Steiglitz, B. M., Scott, I. C., Lebares, C. C., Allen, M. L., Brenner, M. C., Takahara, K. and Greenspan, D. S. (2003). Transforming growth factor-beta induces secretion of activated ADAMTS-2. A procollagen III N-proteinase. J. Biol. Chem. 278, 19549-19557.